None listed
Conditions
Interventions
Intervention1: Tablet Solifenacin: 10mg singal dose
Control Intervention1: Placebo: similar in apperance with intervention tablet. single dose.
Sponsors
Dr Mehdi Ali mirza
Eligibility
Inclusion criteria
Inclusion criteria: 1.Basal Metabolic Index(BMI) 18.5- 25kg/m2 2.Subjects of normal health as determined by medical history and physical examination. 3.Subjects with screening lab values within normal limits or considered insignificant by physician / investigator. 4.Should comply with all study procedures
Exclusion criteria
Exclusion criteria: 1.History of hypersensitivity to any drugs particularly sulfa drugs. 2.History of ingestion of sulfa drugs, prokinetics and loperamide in last 2 weeks. 3.History of ingestion of macrolide antibiotics in last 3 days 4.Regular smoker and has difficulty abstaining from smoking for 48 hours before study 5.Subjects with clinically significant abnormalities / significant disease 6.History of Glaucoma, Urinary or Gastric retention
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time for apperance of Sulfapyridine will be determined by spectrophotometry of salivary samples.Timepoint: Salivary samples will be collected at 2, 3, 4,5,5.5,6,6.5,7, 7.5,8,8.5, 9,10,11,12, 14, 16, 18, 20, 22, 24 hour post sulphasalzine | — |
Secondary
| Measure | Time frame |
|---|---|
| dryness of mouth by visual analogue scale.Timepoint: 2,4,6,8,10,12,14,16,18,20,22,224 hours post sulfasalzine. | — |
Countries
India
Contacts
Public ContactMehdi Ali Mirza
Nizams Institute of Medical Sciences
Outcome results
None listed